Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Multiple Myeloma 55Neoplasms, Plasma Cell 22Central Nervous System Neoplasms 10Prostatic Neoplasms 9Glioblastoma 9Recurrence 8Melanoma 8Brain Neoplasms 8Neoplasms 7Gliosarcoma 7Carcinoma, Non-Small-Cell Lung 7Sarcoma 6Leukemia 6Carcinoma, Hepatocellular 6Waldenstrom Macroglobulinemia 5Myeloproliferative Disorders 5Lung Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Glioma 5Colorectal Neoplasms 5Myelodysplastic-Myeloproliferative Diseases 4Myelodysplastic Syndromes 4Lymphoma 4Liver Neoplasms 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Kidney Neoplasms 4Carcinoma, Renal Cell 4Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myelomonocytic, Chronic 3

Interventions

Darbepoetin alfa 19Epoetin Alfa 17ACE-011 4Cyclosporine 3Busulfan 3luspatercept 2fludarabine phosphate 2fludarabine 2ferric carboxymaltose 2epoetin beta 2continuous erythropoietin receptor activator 2Methotrexate 2Iron-Dextran Complex 2Filgrastim 2Cyclophosphamide 2vactosertib 1thymoglobulin 1ruxolitinib 1roxadustat 1peginesatide 1pegfilgrastim 1niraparib 1leridistim 1iron isomaltoside 1000 1hematide 1ferric gluconate 1eltrombopag 1angiotensin I (1-7) 1Therapeutics 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anemia × Thalidomide × Clear all
NCT00053001 2013-06-26

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 2 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡